智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。
消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72(ActRIIA-Fc融合蛋白)项目，针对肺动脉高压(PAH)适应症的健康人群的多次给药剂量递增(MAD)研究，已顺利完成全部受试者入组。这一进展标志着IMC-003项目的临床开发进程迈出坚实一步，为评估其在多次给药下的安全性、耐受性、药代动力学及药效学特征奠定了重要基础。
据介绍，与现有同类药物相比，IMC-003具有独特的差异化特性。其ActRIIA受体胞外段功能区经过基因工程改造，能够增强与配体Activin A的结合和阻断活性，同时提高药物的质量均一性。在Sugen5416-低氧和MCT诱导的肺动脉高压动物模型中，IMC-003展现出优异的药效且优于现有同类药物。IMC-003对Activin A的高选择性使其在临床应用中有望在更低暴露下取得良好疗效，并可能降低出血风险，展现更好的安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.